CCM® - Who and Where Are the Right Patients?

0 views
November 16, 2022

This session from HFSA 2022 will explain what Cardiac Contractility Modulation therapy is, how it works, and the expected outcomes when utilizing this treatment for HF in NYHA Class III patients who remain symptomatic despite guideline directed medical therapy.

Dr. Andrew Sauer talks about his experiences with CCM® therapy and approaches to identify appropriate candidates in patients with limited options available to improve their symptoms and quality of life.

Comments 0
Login to view comments. Click here to Login